Back to top
more

Leap Therapeutics (LPTX)

(Real Time Quote from BATS)

$3.23 USD

3.23
301,385

-0.04 (-1.22%)

Updated Nov 12, 2024 03:13 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks

by Zacks Equity Research

Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal

by Zacks Equity Research

The NIAID's ACTIV-5/BET-B study evaluating Humanigen's (HGEN) lenzilumab plus remdesivir in hospitalized COVID-19 patients fails to meet the primary endpoint. Stock down.

Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome

by Zacks Equity Research

The FDA bestows an Orphan Drug designation to Amryt's (AMYT) Mycapssa for the treatment of carcinoid syndrome. Stock up in pre-market trading.

Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA

by Zacks Equity Research

The FDA's potential approval of Perrigo (PRGO) unit, HRA Pharma's OTC birth control pills can make the drug the first of its kind to be made available without prescription in the United States.

Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint

by Zacks Equity Research

Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.

Horizon (HZNP) Gets FDA Nod for Krystexxa's Label Expansion

by Zacks Equity Research

The FDA approves Horizon's (HZNP) sBLA for Krystexxa injection plus methotrexate to help people suffering from uncontrolled gout achieve a complete response to therapy.

Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech

by Zacks Equity Research

Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics, and Oncolytics Biotech are part of Zacks Screen of the week article.

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

by Zacks Equity Research

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why

by Zacks Equity Research

The recent setback faced by Acadia's (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with ADP has hurt the stock.

Sanghamitra Saha headshot

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).

Adverum (ADVM) Completes IND Amendment for Gene Therapy Study

by Zacks Equity Research

Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-age-related macular degeneration. Stock up.

Vertex (VRTX) VX-880 Early Study Sees Lifting of Clinical Hold

by Zacks Equity Research

The FDA lifts clinical hold on Vertex's (VRTX) study on VX-880, its stem-cell-derived, fully differentiated islet replacement therapy that could offer a functional cure for type 1 diabetes patients.

Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU

by Zacks Equity Research

Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.

Seagen (SGEN) Up More Than 20% in Past 3 Months: Here's Why

by Zacks Equity Research

Seagen (SGEN) is riding on the strong uptake of its marketed drugs that are approved for different cancer indications. Further label expansion of these drugs should boost the top line.

    Graybug (GRAY) to Review Strategic Alternatives, Stock Up

    by Zacks Equity Research

    Graybug's (GRAY) board of directors is set to review strategic options focused on maximizing shareholder value, including a potential sale of the company. Shares rise.

      Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD

      by Zacks Equity Research

      Cybin (CYBN) receives a "may proceed letter" and IND application clearance from the FDA for a phase I/IIa study evaluating CYB003 for potential treatment of major depressive disorder. Shares up.

      uniQure (QURE) Up on Safety Data From Huntington's Disease Study

      by Zacks Equity Research

      uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.

      Precision BioSciences' (DTIL) Stock Up This Week: Here's Why

      by Zacks Equity Research

      Shares of Precision BioSciences (DTIL) are up as the company inks a gene-editing deal with Novartis to develop a potentially curative treatment for disorders like sickle cell disease.

      Apellis (APLS) Expands Deal for Targeted Complement Therapies

      by Zacks Equity Research

      Apellis (APLS) expands its current research and development deal with privately held company, Affilogic, to develop targeted complement therapies for delivery into the brain.

      Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer

      by Zacks Equity Research

      Exelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with atezolizumab as compared to regorafenib for treating patients with metastatic colorectal cancer.

      Bristol Myers' (BMY) Breyanzi sBLA Receives EMA Validation

      by Zacks Equity Research

      The EMA validates Bristol Myers' (BMY) type II variation application for the label expansion of Breyanzi for treating relapsed/refractory large B-cell lymphoma after first-line therapy.

      Seagen (SGEN) Stock Up on Rumors of Acquisition by Merck

      by Zacks Equity Research

      Shares of Seagen (SGEN) rise after rumors of a buyout by Merck hit the market. However, a deal is not imminent at the moment.

      FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid

      by Zacks Equity Research

      An FDA advisory committee votes against Acadia's (ACAD) Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis.

      Addex (ADXN) Terminates Parkinson's-Related Dyskinesia Study

      by Zacks Equity Research

      Addex (ADXN) terminates the phase IIb/III study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease. Shares fall.

      Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry

      by Zacks Equity Research

      Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.